Microalbuminuria and sRAGE in High-Risk Hypertensive Patients Treated with Nifedipine/Telmisartan Combination Treatment: A Substudy of TALENT
| Autor: | Michael Ochan Kilama, Jasmine Choi, Maria Paola Buzzi, Colomba Falcone, Massimo Torreggiani, Angela D'Angelo, Chiara Boiocchi, Ciro Esposito, Giuseppe Mancia, Sandra Schirinzi, Sara Bozzini |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Předmět: |
Adult
Glycation End Products Advanced Male medicine.medical_specialty Ambulatory blood pressure Adolescent Nifedipine Article Subject Immunology Renal function Benzoates Young Adult Glycation Internal medicine lcsh:Pathology medicine Albuminuria Humans Telmisartan Antihypertensive Agents Aged business.industry Cell Biology Middle Aged medicine.disease Drug Combinations Blood pressure Endocrinology Hypertension Benzimidazoles Female Microalbuminuria medicine.symptom business lcsh:RB1-214 Research Article medicine.drug |
| Zdroj: | Mediators of Inflammation Mediators of Inflammation, Vol 2012 (2012) |
| ISSN: | 0962-9351 |
| DOI: | 10.1155/2012/874149 |
| Popis: | Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|